Comparing primary prevention with secondary prevention to explain decreasing Coronary Heart Disease death rates in Ireland, 1985–2000 by Kabir, Zubair et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Public Health
Open Access Research article
Comparing primary prevention with secondary prevention to 
explain decreasing Coronary Heart Disease death rates in Ireland, 
1985–2000
Zubair Kabir1, Kathleen Bennett*2, Emer Shelley3, Belgin Unal4, 
Julia A Critchley5 and Simon Capewell6
Address: 1Harvard School of Public Health, Division of Public Health Practice, Boston, USA, 2Department of Pharmacology & Therapeutics, Trinity 
Centre for Health Sciences, St. James's Hospital, Dublin, Ireland, 3Department of Health & Children, Hawkins House, Dublin, Ireland, 
4Department of Public Health, Dokuz Eylul University School of Medicine, Izmir, Turkey, 5School of Population and Health Sciences, University 
of Newcastle upon Tyne, UK and 6Department of Public Health, University of Liverpool, Liverpool, UK
Email: Zubair Kabir - zkabir@hsph.harvard.edu; Kathleen Bennett* - bennettk@tcd.ie; Emer Shelley - emer.shelley@mailf.hse.ie; 
Belgin Unal - belgin.unal@deu.edu.tr; Julia A Critchley - J.A.Critchley@newcastle.ac.uk; Simon Capewell - capewell@liverpool.ac.uk
* Corresponding author    
Abstract
Background:  To investigate whether primary prevention might be more favourable than
secondary prevention (risk factor reduction in patients with coronary heart disease(CHD)).
Methods: The cell-based IMPACT CHD mortality model was used to integrate data for Ireland
describing CHD patient numbers, uptake of specific treatments, trends in major cardiovascular risk
factors, and the mortality benefits of these specific risk factor changes in CHD patients and in
healthy people without recognised CHD.
Results:  Between 1985 and 2000, approximately 2,530 fewer deaths were attributable to
reductions in the three major risk factors in Ireland. Overall smoking prevalence declined by 14%
between 1985 and 2000, resulting in about 685 fewer deaths (minimum estimate 330, maximum
estimate 1,285) attributable to smoking cessation: about 275 in healthy people and 410 in known
CHD patients. Population total cholesterol concentrations fell by 4.6%, resultingin approximately
1,300 (minimum estimate 1,115, maximum estimate 1,660) fewer deaths attributable to dietary
changes(1,185 in healthy people and 115 in CHD patients) plus 305 fewer deaths attributable to
statin treatment (45 in people without CHD and 260 in CHD patients). Mean population diastolic
blood pressure fell by 7.2%, resulting in approximately 170 (minimum estimate 105, maximum
estimate 300) fewer deaths attributable to secular falls in blood pressure (140 in healthy people and
30 in CHD patients), plus approximately 70 fewer deaths attributable to antihypertensive
treatments in people without CHD.
Of all the deaths attributable to risk factor falls, some 1,715 (68%) occurred in people without
recognized CHD and 815(32%) in CHD patients.
Conclusion:  Compared with secondary prevention, primary prevention achieved a two-fold
larger reduction in CHD deaths. Future national CHD policies should therefore prioritize
nationwide interventions to promote healthy diets and reduce smoking.
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Background
Coronary heart disease (CHD) remains the largest single
cause of death in Ireland, as elsewhere in Europe, the USA
and Australasia [1]. However, since the 1980s, CHD mor-
tality rates have halved in Ireland, similar to many indus-
trialised countries [1]. Studies in Europe, the USA and
New Zealand consistently suggest that 50%–75% of the
decrease in cardiac deaths can be attributed to popula-
tion-wide improvements in the major risk factors, partic-
ularly smoking, total cholesterol and blood pressure [2-5].
The remaining 25%–50% of the decreased mortality fall
[2-5] is generally explained by modern cardiology treat-
ments for known CHD patients, such as thrombolysis,
ACE inhibitors, statins, and coronary artery bypass sur-
gery.
Consultants and department of health officials in particu-
lar prioritise risk factor reduction in CHD patients (sec-
ondary prevention), citing the low numbers needed to
treat. However, epidemiological principles suggest that
primary prevention (risk factor reduction in healthy sub-
jects) may have a bigger potential than secondary preven-
tion to reduce CHD deaths [6]. Although primary and
secondary prevention interventions are probably both
necessary to maximise population health, [4,6,7]quantify-
ing their relative contributions is difficult using observa-
tional data [8]. Researchers have therefore used models to
quantify the potential contribution of risk factor reduc-
tions before and after CHD manifests in an individual
[2,8,9].
A better understanding of the relative contributions of pri-
mary prevention and secondary prevention to the recent
decrease in CHD deaths is clearly very important. This
would help to inform future CHD policy options in Ire-
land and elsewhere [10]. We have therefore used a vali-
dated and comprehensive CHD mortality model for
Ireland to analyze the CHD mortality decrease between
1985 and 2000 [11]. We estimated the deaths avoided by
changes in major cardiovascular risk factors in a) appar-
ently healthy individuals ("primary prevention") and b)
in patients with CHD ("secondary prevention") similar to
a recent UK study [9].
Methods
The IMPACT CHD mortality model
The cell-based IMPACT CHD mortality model, previously
validated in England and Wales [4], Scotland [3], New
Zealand [5], Beijing [12], Finland [13], and now in Ire-
land [11], is described in detail on the IMPACT website
[14]. In brief, the model was used to integrate data for the
Irish population of 3.8 million, between 1985 and 2000.
We attempted to include all individuals aged between 25
and 84 years, describing:
a) CHD patient numbers (ICD-9 code: 410–414), b)
uptake and effectiveness of specific treatments, c) trends
in major cardiovascular risk factors in apparently healthy
subjects in populations and in specific patient groups, and
d) the effectiveness (mortality benefits) of the reductions
in specific risk factors in individuals with and without rec-
ognised CHD [11,14].
Data sources
Information was obtained from routine health statistics,
mainly the Public Health Information System (PHIS)
[15], available from the Department of Health and Chil-
dren, Ireland. Hospital Inpatient Enquiry (HIPE) data col-
lected by the Economic and Social Research Institute were
used though the system does not differentiate between
first and recurrent events [16]. Prescription data were
obtained from the General Medical Services (GMS) Pay-
ments Board and risk factor data mainly from two popu-
lation studies, the Kilkenny Health Project and the Cork
and Kerry Diabetes and Heart Disease Study [17,18], as
well as from the Central Statistics Office [19]. Data on the
effectiveness of therapeutic interventions and the mortal-
ity reduction from specific population cardiovascular risk
factor changes came from recent published meta-analyses
randomised controlled trials, and cohort studies [20-22].
Further details on the Irish data sources are in appendices
1–3 [see Additional file 1].
Primary prevention estimates in people without 
recognized CHD
The Irish IMPACT CHD Mortality model calculated the
numbers of CHD deaths prevented/postponed using a
similar methodology recently undertaken in England and
Wales [9]. For risk factor changes, the model uses regres-
sion (β) coefficients obtained from large meta-analyses
and cohort studies [13,22,23]. The details are shown in
Appendix 4 [see Additional file 1]. Given the absence of
suitable β coefficients for obesity, diabetes, and physical
activity, relative risk estimates were used. However, for the
present study only the three main cardiovascular risk fac-
tors (cholesterol, smoking and blood pressure) were con-
sidered, along with hypertension and statin treatments.
All the regression coefficients and relative risk values were
obtained from multivariate logistic regression analyses
and were therefore assumed to be independent, having
adjusted for potential confounding from other major risk
factors [13,22,23].
Each  β coefficient quantifies the independent relation
between population change in a specific CHD risk factor
(such as smoking, cholesterol, or blood pressure)and the
consequent percentage change in population mortality
from CHD. We then estimated the subsequent reduction
in the number of deaths produced by the decrease in each
major risk factor as the product of three variables: theBMC Public Health 2007, 7:117 http://www.biomedcentral.com/1471-2458/7/117
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number of CHD deaths observed in the base year (1985),
the relative reduction in that risk factor, and the β coeffi-
cient, each stratified by age and sex [11,14].
To estimate the impact of the population-wide reduction
in cholesterol due to dietary change, we subtracted the
estimated effect of statins for primary prevention from the
overall number of deaths prevented or postponed in the
population due to change in mean cholesterol concentra-
tion. We explicitly considered demographic change by
using age and sex specific population CHD mortality and
CHD patient numbers for 1985 and for 2000 [11].
Secondary prevention estimates in CHD patients
The mortality benefit attributable to reductions in each
major risk factor (smoking, total cholesterol, and blood
pressure) in each group of CHD patients were estimated
as the number of deaths prevented or postponed similar
to the calculation for effects on primary prevention. How-
ever, for secondary prevention in CHD patients, we used
relative risks for the three main risk factors studied which
were different from the beta coefficients employed for pri-
mary prevention estimates. The estimates used for second-
ary prevention are relatively low than those given in
Appendix 4 [see Additional file 1] that were used for pri-
mary prevention estimates. We estimated the number of
deaths prevented or postponed for specific age and sex
groups. We used survival benefit over a one year time
interval throughout.
We categorised CHD patients according to disease groups:
acute myocardial infarction, survivors of myocardial inf-
arction, revascularisation patients, and patients with
unstable angina, chronic angina, and chronic heart fail-
ure. We did not consider the impact of changes in risk fac-
tors in patients with an initial acute myocardial infarction
or unstable angina, because both are transient states. To
avoid double counting, we firstly made adjustments for
overlaps between different treatment groups by subtract-
ing the overlapping subgroup from the main group
[11,14].
We based age and sex specific smoking cessation rates on
local surveys and audits. We initially assumed that age
and sex specific changes in cholesterol attributable to diet
and changes in blood pressure attributable to population
secular trends would mirror the changes seen in the gen-
eral population. We then used rigorous sensitivity analy-
ses to test the effect of much smaller (-50%) and much
larger (+50%) changes.
Statins and other treatments
The model aimed to include all medical and surgical treat-
ments provided in 2000. This included statins as primary
prevention (in people without recognised CHD) and as
secondary prevention(in CHD patients). We calculated
the absolute reduction in mortality by using the relative
reduction in mortality reported in the most recent meta-
analysis [20] applied to the age specific case fatality rate
observed in unselected patient cohorts. The effect of all
other "secondary prevention" drugs (aspirin, β blockers,
and angiotensin converting enzyme inhibitors) has been
previously reported and was explicitly excluded from this
analysis [11]. We did not consider over the counter stat-
ins, as these only became available in 2003.
Sensitivity analysis
Because of the uncertainties surrounding some values, we
did a multiway sensitivity analysis using the analysis of
extremes method [24].
Apportioning deaths prevented or postponed between 
primary and secondary prevention
We then estimated the deaths prevented or postponed in
apparently healthy people as the deaths prevented or
postponed in the entire population minus the deaths pre-
vented or postponed in each CHD patient group.
Results
CHD mortality declines between 1985 and 2000 due to risk 
factor reductions
Between 1985 and 2000, about 2,530 fewer deaths were
attributable to reductions in the three major cardiovascu-
lar risk factors in Ireland. Approximately 1,715 deaths
(minimum estimate 1,195, maximum estimate 2,370) were
prevented or postponed due to decreases in the three
major risk factors: smoking, cholesterol and blood pres-
sure among apparently 'healthy individuals' (primary pre-
vention); that includes both statin (45 fewer deaths) and
hypertension therapy (70 fewer deaths) (Table 1). A fur-
ther 815 deaths (minimum estimate 500, maximum estimate
1,635) were attributed to changes in these three risk fac-
tors in recognized CHD patients (secondary prevention),
including 260 fewer deaths due to statin therapy.
Overall smoking prevalencedeclined by 14% between
1985 and 2000, resulting in about 685 fewer deaths (min-
imum estimate 330, maximum estimate 1,285) attributable
to smoking cessation: about 275 in healthy people and
410 in known CHD patients. Population total cholesterol
concentrations fell by 4.6%, resulting in approximately
1,300 (minimum estimate 1,115, maximum estimate 1,660)
fewer deaths attributable to dietary changes (1,185 in
healthy people and 115 in CHD patients) plus 305 fewer
deaths attributable to statin treatment (45 in people with-
out CHD and 260 in CHD patients). Mean population
diastolic blood pressure fell by 7.2%, resulting in approx-
imately 170 (minimum estimate 105, maximum estimate
300) fewer deaths attributable to secular falls in blood
pressure (140 in healthy people and 30 in CHD patients),BMC Public Health 2007, 7:117 http://www.biomedcentral.com/1471-2458/7/117
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plus approximately 70 fewer deaths attributable to antihy-
pertensive treatments in people without CHD.
Of all the deaths attributable to risk factor falls, some
1,715 (68%) occurred in people without recognized CHD
and 815 (32%) in CHD patients.
The relative contribution to the overall decline in CHD
deaths from primary and secondary prevention for each
risk factor was little changed whether considering best,
minimum, or maximum estimates (sensitivity analyses)
(Table 1). A similar pattern was also observed in both
men and women across all age-groups (Table 2). How-
ever, the overall contribution from primary prevention
was consistently higher in all age groups for both sexes
(Table 2).
Discussion
More than two-thirds of the large reduction in CHD
deaths in Ireland between 1985 and 2000 may be attrib-
uted to primary prevention, defined here as reductions in
the three major risk factors (smoking, cholesterol and
blood pressure) in individuals without recognised CHD.
Furthermore, primary prevention had more than two-fold
greater impact than secondary prevention (defined here as
risk factor reductions in recognised CHD patients). This is
much as predicted by Rose [6], and others [8]. A recent
study in Ireland also showed that twice as many life-years
were generated by relatively modest reductions in the
three major cardiovascular risk factors when compared
with the use of modern cardiology treatments [25].
Reductions in the three major cardiovascular risk factors
(cholesterol, smoking and blood pressure) between 1985
and 2000 accounted for about 2,530 fewer deaths in Ire-
land in 2000. The two biggest contributions came from
large decreases in smoking prevalence and cholesterol lev-
els. This resulted in about 2,290 fewer deaths, of which
about 1,505 were in "healthy subjects", while approxi-
Table 2: Numbers of deaths prevented or postponed by risk 
factor reductions:Relative contributions from primary 
prevention and secondary prevention, by age and sex
AGE GROUPS TOTAL
MEN 45–64 years 65–84 years
Risk Factor TOTAL 585 1,030 1,615**
Secondary Prevention 190 325 515
Primary Prevention 395 705 1,100
Secondary prevention (%) 32% 32% 32%
Primary prevention (%) 68% 68% 68%
AGE GROUPS TOTAL
WOMEN 45–64 years 65–84 years
Risk Factor TOTAL 145 725 870
Secondary Prevention 55 245 300
Primary Prevention 90 480 570
Secondary prevention (%) 38% 34% 34%
Primary prevention (%) 62% 66% 66%
*All numbers rounded to the nearest 5
**In 25–44 year-olds only 45 fewer CHD deaths occurred, and 
therefore not shown in this table.
Table 1: The CHD mortality fall in Ireland attributable to risk factor changes in individuals with and without recognised coronary heart 
disease, including sensitivity analyses (minimum and maximum estimates)
Relative change in 
population risk 
factor level (%)
Deaths prevented or 
postponed * (minimum 
and maximum estimates)
In healthy subjects 
(Primary prevention)
In CHD patients 
(Secondary 
Prevention)
TOTALS
SMOKING Total Change -14.2% 275 (20–485) 410 (310–800) 685 (330 – 1,285)
CHOLESTEROL Total change -4.6% 1,230 (1060–1,520) 375 (170–770) 1,605 (1,230 – 2,290)
Fall Attributable to diet 1,185 (1050–1,445) 115 (65–215) 1,300 (1,115–1,660)
Fall Attributable to statins 45 (10–75) 260 (105–555) 305 (115–630)
BLOOD PRESSURE Total Change -7.2% 210 (115–365) 30 (20–65) 240 (135–430)
Secular trends 140 (85–235) 30 (20–65) 170 (105–300)
Hypertension therapy 70 (30–130) ** 70 (30–130)
All 3 major risk factors 1,715(68%) (1,195–2,370) 815(32%) (500–1,635) 2,530 (1,695–4,005)
*All numbers were rounded to the nearest 5;
**Hypertension therapy in CHD patients already quantified within the secondary prevention medication component of the IMPACT Model.BMC Public Health 2007, 7:117 http://www.biomedcentral.com/1471-2458/7/117
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mately 410 and 115 fewer deaths resulted from smoking
cessation and from diet-based cholesterol reductions in
CHD patients, respectively and the remainder from blood
pressure reductions. Abramson and Wright, in a meta-
analysis of randomised trials in a primary prevention pop-
ulation, found that statin therapy did not reduce total
CHD events in women or in all those over 69 years of age
[26]. Instead, modification of lifestyles to reduce choles-
terol was considered more acceptable, as shown in our
study, by the greater benefits of diet change in the primary
prevention population in reducing cholesterol. In con-
trast, there were greater benefits observed in reducing cho-
lesterol, by prescribing statins in the secondary prevention
population. This contrasting pattern is likely to reflect the
differences in cardiovascular risk and potential benefits of
treatment versus lifestyle changes in those with and with-
out CHD.
Opportunities for secondary prevention are frustratingly
limited, because some 50% of myocardial infarctions are
rapidly fatal [27]. This emphasises the importance of pri-
mary prevention. It makes sense to energetically target
smokers before they develop clinical disease. In Ireland,
the National Workplace Smoking Ban introduced in
March 2004 has already achieved significant improve-
ments in smoking prevalence and in air quality [28,29].
Irish population levels of both cholesterol and blood
pressure declined between 1985 and 2000 [11]. The fac-
tors underlying these declines are clearly complex. Having
explicitly considered all the cardiology therapeutic inter-
ventions in our main IMPACT CHD mortality model
[9,11], the residual decline in total cholesterol levels
might reasonably be attributed to dietary changes [30].
Reduced intake of saturated fat and salt will also have ben-
efited population blood pressure [31]. Recent improve-
ments in physical activity levels were, however, minor
[32]. Randomised trials demonstrate that it is hard to
achieve substantial and sustained changes in dietary hab-
its in individuals [33,34]. Substantial falls in average total
cholesterol have been achieved in entire populations
including Finland, Mauritius and Poland [30,35,36].
These falls almost certainly reflect a combination of fac-
tors: national policy, economics, health promotion and
multisectoral collaboration, as well as advice to individu-
als [30,35,36]. International evidence is thus increasingly
powerful.
The most effective interventions to reduce major risk fac-
tors have come from comprehensive cardiovascular strat-
egies underpinned by robust national policies [35,36].
The 1999 Irish Cardiovascular Health Strategy is compre-
hensive, outlining a wide range of recommendations,
including a secondary prevention programme [10]. Such
programmes appear cost-effective [8,34].
Our study findings also show that preventative
approaches do not have a sex difference in preventing or
postponing CHD deaths in Ireland (Table 2). The major-
ity of such preventable deaths occurred among the oldest
age-groups (65–84 years). However, further reductions in
preventable CHD deaths could be achieved in Ireland and
elsewhere if potentially younger individuals (both appar-
ently healthy and at risk) are also targeted. The relatively
low contribution to fewer CHD deaths through secondary
prevention in this study also highlights the importance of
strengthening secondary prevention programmes in Ire-
land.
The study findings strongly support the population pre-
vention approach [6,8]. Over 20 years ago, Rose clearly
demonstrated that apparently small changes across the
entire population would achieve far larger overall mortal-
ity gains than much greater changes in a relatively small
number of high risk individuals [6]. The evidence base
underlying the IMPACT CHD mortality model is now
strengthened by several recent studies [10,20,23].
Limitations of the study
All modelling analyses should be interpreted with appro-
priate caution. All require numerous data inputs, each
with recognized limitations. We therefore sometimes had
to use data from studies possibly constrained by geo-
graphic or selection bias, or extrapolate to older age
groups, or make explicit assumptions. However, our rigor-
ous analysis of extremes approach suggested that the pro-
portional contributions to the overall reductions in deaths
from primary versus secondary prevention remained rea-
sonably consistent, irrespective of whether best, mini-
mum, or maximum estimates were considered. This was
reassuring, as was the general consistency with studies
performed elsewhere [3-5,13]. Furthermore, we only con-
sidered the three main risk factors in this study although
the IMPACT CHD mortality model does account for the
remaining risk factors (obesity, diabetes and physical
inactivity levels) and also for all the cardiology treatments
[9,11,25]. Specific parameters such as LDL/HDL or TC/
HDL ratios were not considered. This merits further work.
Conclusion
In conclusion, more than two-thirds of the recent large
falls in CHD deaths in Ireland can be attributed to
improvements in the levels of the three main cardiovascu-
lar risk factors. Much as predicted, primary prevention
had a two-fold bigger mortality impact than risk factor
reduction in CHD patients. Comprehensive CHD strate-
gies should emphasize that primary prevention is also
cost-effective. Tobacco control, healthier diets and physi-
cal activity should therefore be prioritised in future
national CHD strategies, especially targeting relatively
young populations. Moreover, further reductions in CHDBMC Public Health 2007, 7:117 http://www.biomedcentral.com/1471-2458/7/117
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deaths could be achieved if secondary prevention pro-
grammes were also strengthened.
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